MAGEA2 and breast cancer: MAGEA2, MAGEA3, MAGEA4, MAGEA6, and MAGEA12 are up-regulated in the CDKN2A alteration group, amongst which MAGEA3 (HR=1.61[1.27-2.04], p=8.2e-5), MAGEA4 (HR=1.38[1.08-1.77], p=0.011), and MAGEA12 (HR=1.65[1.10-2.48], p=0.015) are accompanied by worse prognosis in breast cancer (Figure 13C–13E).